Pulmonx Corporation (LUNG)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Glendon E. French
|
CEO, President & Director | 319.52k | -- | 1962 |
|
Dr. Derrick Sung Ph.D.
|
CFO & COO | 283.39k | -- | 1973 |
|
Mr. David A. Lehman J.D.
|
General Counsel & Secretary | 516.64k | -- | 1961 |
|
Mr. Srikanth Radhakrishnan
|
Chief Science & Technology Officer | -- | -- | 1973 |
|
Ms. Marcee M. Maroney
|
Vice President of Marketing | -- | -- | 1970 |
|
Mr. Jérôme Erath
|
Senior VP & GM of International | -- | -- | -- |
|
Mr. Geoffrey Beran Rose
|
Chief Commercial Officer | 632.29k | -- | 1974 |
|
Dr. Narinder S. Shargill Ph.D.
|
Senior Vice President of Global Medical & Clinical Affairs | -- | -- | 1955 |
|
Mr. John B. McKune
|
VP of Finance & Corporate Controller | -- | -- | 1976 |
Pulmonx Corporation
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 296
Description
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Corporate Governance
Upcoming Events
October 27, 2026 at 8:00 PM UTC
Pulmonx Corporation Earnings Date
Recent Events
May 19, 2026 at 12:00 AM UTC
SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
